FDA approves topical gel to treat overactive bladder

Article

Oxybutynin chloride 10% topical gel (Gelnique) has received FDA approval for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Oxybutynin chloride 10% topical gel (Gelnique) has received FDA approval for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

The gel was developed to provide OAB patients with an alternative to currently available oral treatment options. Because the drug is delivered transdermally, it is not metabolized by the liver in the same way as orally administered oxybutynin. The goal is to reduce side effects, including dry mouth and constipation, according to the drug’s manufacturer, Watson Pharmaceuticals.

The drug’s approval was based on a phase III randomized, double-blind, placebo-controlled, parallel group trial that evaluated 789 patients with signs and symptoms of OAB. During the 12-week trial, a 1-gram, once-daily dose of oxybutynin chloride 10% gel was found to be more effective than placebo at relieving OAB symptoms, including reducing incontinence episodes and urinary frequency, and increasing urine void volume.

Related Videos
Keyan Salari, MD, PhD, answers a question during a Zoom video interview
Scott Morgan, MD, MSc, FRCPC, answers a question during a Zoom video interview
Illustration of prostate | Image Credit: © Judith - stock.adobe.com
Megan S. Bradley, MD, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Daniel J. Heidenberg, MD, answers a question during a Zoom video interview
African American patient explaining issues to Asian doctor using tablet | Image Credit: © rocketclips - stockadobe.com
© 2024 MJH Life Sciences

All rights reserved.